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Background
The diversity in nature has long been and still is one of the
biggest resources of pharmaceutical lead compounds and
many natural products often exhibit biological activity
against unrelated biological targets, thus providing us with
starting points for drug development. Natural peptides of
great number and diversity occur in all organisms from
plants to microbes to man. Examples for such rich and yet
largely untapped libraries of bioactive compounds are ani-
mal venom peptides, insect peptide hormones or plant
defense peptides [1]. Our goals are (i) to discover and
characterize novel bioactive peptides, (ii) to screen their
pharmacological activity in vitro, (iii) to synthesize opti-
mized peptide compounds and (iv) to determine their
potential as pre-clinical drug candidates.
Methods
As proof-of-concept we have used a genome-mining
approach or mass spectrometry and peptidomics to
determine the occurrence and molecular structure of
naturally-occurring peptides and have investigated their
pharmacological profile on human oxytocin and vaso-
pressin receptors, representative members of the GPCR
family, as well as their anti-proliferative activity on cells
of the human immune system. Circular plant peptides
have been identified as potent immunosuppressive agents
and promise great potential as templates for pharmaceu-
tical applications due to their enormous stability and
sequence diversity [2]. On the other hand we are explor-
ing the pharmacological potential of endogenous insect
vasotocin-like peptide hormones and marine cone-snail
venom peptides as receptor-subtype selective ligands for
the treatment of a wide range of challenging, but yet
untreatable diseases.
Discussion
Unlike small molecules, peptides are just at the beginning
as potential drug sources and still face a range of signifi-
cant drug development challenges including efficient drug
delivery, oral bioavailability and central penetration.
Nevertheless, the ease of synthesis, the vast natural abun-
dance of bioactive peptides and their immense pharmaco-
logical potential are so convincing that it is just a question
of time until peptides can be utilized as orall bioavailable
or even CNS-penetrating drugs together with an efficient
delivery platform preserving their selectivity and interac-
tion with extracellular targets, yet simultaneously retaining
stability to enzymatic degradation.
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